UBS analyst Andrew Mok raised the firm’s price target on Encompass Health to $73 from $68 and keeps a Buy rating on the shares. The firm thinks Encompass is set up well to beat and raise in 2023 with the high-end of guidance significantly more realistic than the low-end, the analyst tells investors in a research note.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Published first on TheFly
See today’s best-performing stocks on TipRanks >>
Read More on EHC:
- Encompass Health sees FY23 adjusted EPS $2.87-$3.16, consensus $3.25
- Encompass Health reports results for fourth quarter 2022 and issues full-year 2023 guidance
- Encompass Health reports Q4 adjusted EPS 88c, consensus 83c
- Encompass Health added to Analyst Current Favorites list at Raymond James
- Encompass Health plans to build 50-bed inpatient rehab hospital in RI